The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Abstract
Background Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients. Objective To compare Sativex with placebo in relieving symptoms of spasticity due to MS. Methods A 15-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study in 337 subjects with MS spasticity not fully relieved with current anti-spasticity therapy. Results The primary endpoint was a spasticity 0-10 numeric rating scale (NRS). Intention-to-treat (ITT) analysis showed a non-significant improvement in NRS score, in favor of Sativex. The per protocol (PP) population (79% of subjects) change in NRS score and responder analyses (> or =30% improvement from baseline) were both significantly superior for Sativex, compared with placebo: -1.3 versus -0.8 points (change from baseline, p=0.035); and 36% versus 24% (responders, p=0.040). These were supported by the time to response (ITT: p=0.068; PP: p=0.025) analyses, carer global impression of change assessment (p=0.013) and timed 10-meter walk (p=0.042). Among the subjects who achieved a > or =30% response in spasticity with Sativex, 98, 94 and 73% reported improvements of 10, 20 and 30%, respectively, at least once during the first 4 weeks of treatment. Sativex was generally well tolerated, with most adverse events reported being mild-to-moderate in severity. Discussion and conclusions The 0-10 NRS and responder PP analyses demonstrated that Sativex treatment resulted in a significant reduction in tr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although these five studies found improvements in nausea with cannabis use, other studies found nausea to be an adverse event associated with cannabis use among some participants.”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [49]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
(1965) · PubMed · Cited by 14,925
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,424
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
The Barthel ADL Index: A reliability study
Collin, C., Wade, D. T., Davies, S., & Horne, V. (1988) · International Disability Studies · doi:10.3109/09638288809164103 · Cited by 2,734
Self-citationWhat is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis, S., & Campbell, F. (1999) · BMJ · doi:10.1136/bmj.319.7211.670 · Cited by 2,160
Clinical applications of visual analogue scales: a critical review
McCormack, H. M., de L. Horne, D. J., & Sheather, S. (1988) · Psychological Medicine · doi:10.1017/s0033291700009934 · Cited by 2,108
Research works printed but not linked: 2
- Wade D, 2004, Mult Scler, 10, 1
- Mahoney Fl, 1965, Maryland State Med J, 14, 56
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
(2014) · Neurology · doi:10.1212/wnl.0000000000000363 · Cited by 553
“One Class II multicenter study randomized 337 subjects to receive nabiximols or placebo.(10) The primary outcome was the change from baseline in mean NRS (0–10) assessed at treatment weeks 2, 6, 10, and 14.”
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Self-citationStockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Metadata
- Authors
- Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., & Ambler, Z.
- Affiliations
- Royal Berkshire Hospital (GB)
- ORCID
- Venue
- Neurological Research
- Publisher
- Informa UK Limited
- Published
- 2010-06
- Volume
- 32
- Issue
- 5
- Pages
- 451-459
- ISSN
- 0161-6412 (ISSN-L)
- 1743-1328
- OpenAlex
- W2043053000
- Cited by
- 283
- References
- 35
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 16 · 2023: 15 · 2022: 24 · 2021: 17 · 2020: 26 · 2019: 14 · 2018: 31 · 2017: 23 · 2016: 18 · 2015: 16 · 2014: 24 · 2013: 10 · 2012: 21
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurological Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Keywords
- Sativex, nabiximols, multiple sclerosis, spasticity, cannabis-based medicines, responder analysis, adverse events, tolerability
- MeSH terms
- Mental Disorders, Cannabidiol, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis, Muscle Spasticity, Neuromuscular Agents, Plant Extracts, Severity of Illness Index, Dronabinol, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. https://app.cochat.ai/papers/10.1179/016164109x12590518685660
- The paper
- Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., & Ambler, Z. (2010). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research. https://doi.org/10.1179/016164109x12590518685660
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.